Cargando…

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

Detalles Bibliográficos
Autores principales:	Dieci, Maria Vittoria, Bisagni, Giancarlo, Bartolini, Stefania, Frassoldati, Antonio, Vicini, Roberto, Balduzzi, Sara, D’amico, Roberto, Conte, Pierfranco, Guarneri, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097682/ https://www.ncbi.nlm.nih.gov/pubmed/37045875 http://dx.doi.org/10.1038/s41523-023-00532-3

Ejemplares similares

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
por: Conte, PierFranco, et al.
Publicado: (2023)

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
por: Dieci, M V, et al.
Publicado: (2019)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
por: Guarneri, V, et al.
Publicado: (2019)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
por: Miglietta, Federica, et al.
Publicado: (2022)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
por: Urso, Loredana, et al.
Publicado: (2021)

Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
por: Guarneri, V., et al.
Publicado: (2022)

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
por: Solinas, Cinzia, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
por: Shen, Xia-Bo, et al.
Publicado: (2021)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
por: Wu, Xian-Meng, et al.
Publicado: (2023)

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
por: Thanopoulou, Eirini, et al.
Publicado: (2020)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
por: Jeong, Eunae, et al.
Publicado: (2021)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2023)

Effect of HER2 expression status on the prognosis of patients with HR(+)/HER2(‑) advanced breast cancer undergoing advanced first‑line endocrine therapy
por: Wang, Kan, et al.
Publicado: (2023)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
por: Salvo, Elizabeth M., et al.
Publicado: (2021)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
por: Davie, Alison, et al.
Publicado: (2023)

Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients
por: Huang, Tzu-Ting, et al.
Publicado: (2018)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7il2bafku34jnh6r67cngdn1lb